Sign In
Buy COGT
$32.26
-0.500 (-1.53%)
At Close: Jun 03, 2026
WALTHAM, Mass. and BOULDER, Colo.
Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
04:31pm, Tuesday, 25'th Mar 2025
Four abstracts accepted for poster presentation highlight Cogent's expertise in pioneering best-in-class therapeutics Four abstracts accepted for poster presentation highlight Cogent's expertise in pi
Is Cogent Biosciences (COGT) Stock a Solid Choice Right Now?
09:35am, Thursday, 20'th Mar 2025
Cogent Biosciences (COGT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Cogent Biosciences Announces Participation in the Leerink Healthcare Conference
08:00am, Friday, 07'th Mar 2025
WALTHAM, Mass. and BOULDER, Colo.
Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
08:00am, Thursday, 27'th Feb 2025
65% mean improvement in Total Symptom Score (TSS) at 48 weeks, including 88% of patients achieving at least a 50% reduction in TSS Top-line results from Summit Part 2 registration-directed trial on tr
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
08:00am, Tuesday, 25'th Feb 2025
• Top-line results from SUMMIT trial in NonAdvSM patients expected July 2025 • APEX trial enrollment in AdvSM patients complete; top-line results expected in 2H 2025 • Top-line results from
Is Cogent Biosciences (COGT) Outperforming Other Medical Stocks This Year?
10:40am, Tuesday, 11'th Feb 2025
Here is how Cogent Biosciences, Inc. (COGT) and Cardiol Therapeutics Inc. (CRDL) have performed compared to their sector so far this year.
WALTHAM, Mass. and BOULDER, Colo., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically define
3 Biotech Stocks With Notable Insider Buying
12:29pm, Wednesday, 22'nd Jan 2025
Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-c
Cogent Biosciences: Buy The Pullback For Bezuclastinib's 2025 SM And GIST Data
03:27am, Saturday, 18'th Jan 2025
Bezuclastinib is COGT's main value driver, currently undergoing 3 late-stage trials for SM and GIST. COGT's SUMMIT Part 2 for nonAdvSM will give us decisive data in July 2025, which I consider its mai
Why Is Cogent Biosciences Stock Trading Higher On Monday?
12:52pm, Monday, 09'th Dec 2024
On Sunday, Cogent Biosciences, Inc. COGT revealed updated clinical results from the Open Label Extension (OLE) portion of the SUMMIT trial of bezuclastinib in patients with non-advanced systemic mas
56% mean improvement in Total Symptom Score (TSS) at 24 weeks with 76% of patients achieving at least a 50% reduction in TSS
52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID 88% ORR per PPR criteria, including 100% ORR for patients receiving 100 mg BID Median time to response 2.2 months with me
Cogent (COGT) Up on SUMMIT Study Update Post Positive FDA Meeting
10:20am, Friday, 28'th Jun 2024
Cogent (COGT) announces a positive FDA meeting and alignment on MS2D2, a novel patient-reported outcome measure for the SUMMIT study. The company's shares rise on the news.
Patients treated with 100 mg bezuclastinib showed substantial reduction in their most severe symptoms and mast cell reactions
